Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$35.88
-0.6%
$47.93
$15.80
$94.90
$2.56B-1.31847,760 shs593,729 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,017.68
+3.0%
$940.54
$623.78
$1,133.95
$930.53B0.483.47 million shs3.79 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$28.40
-1.0%
$33.21
$22.96
$43.15
$3.33B0.722.40 million shs1.80 million shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-0.64%-5.18%-29.30%-47.51%+43.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+2.92%+2.78%+9.79%-0.38%+34.80%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-1.01%-9.32%-19.32%-5.80%+3.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$35.88
-0.6%
$47.93
$15.80
$94.90
$2.56B-1.31847,760 shs593,729 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,017.68
+3.0%
$940.54
$623.78
$1,133.95
$930.53B0.483.47 million shs3.79 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$28.40
-1.0%
$33.21
$22.96
$43.15
$3.33B0.722.40 million shs1.80 million shs
Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-0.64%-5.18%-29.30%-47.51%+43.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+2.92%+2.78%+9.79%-0.38%+34.80%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-1.01%-9.32%-19.32%-5.80%+3.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2.89
Moderate Buy$109.25204.49% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,218.3319.72% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.85
Moderate Buy$95.50236.27% Upside

Current Analyst Ratings Breakdown

Latest LLY, VKTX, and GPCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B-)Buy (B)
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,325.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,350.00 ➝ $1,400.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight$1,344.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Lower Price TargetBuy$1,294.00 ➝ $1,133.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,205.00 ➝ $1,230.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,260.00 ➝ $1,283.00
5/1/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Reiterated RatingBuy$125.00
(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$20.43 per shareN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B14.70$25.89 per share39.31$33.13 per share30.72
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$4.32 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1536.1523.011.0734.98%105.77%23.76%8/5/2026 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)

Latest LLY, VKTX, and GPCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.39-$0.35+$0.04-$0.35$11.11 millionN/A
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/29/2026Q1 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.01-$1.37-$0.36-$1.37N/AN/A
2/26/2026Q4 2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.35-$0.49-$0.14$999.00$7.14 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.68%+15.18%24.58%11 Years
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest LLY, VKTX, and GPCR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
26.16
26.16
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
5.72
5.72

Institutional Ownership

CompanyInstitutional Ownership
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
91.78%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
5.60%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
13670.84 million66.88 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20116.11 million109.95 millionOptionable

Recent News About These Companies

Three Biotechs That Are Top Takeover Targets
LGND: 1Q:26 Results Highlight Breadth of Portfolio

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$35.88 -0.23 (-0.64%)
Closing price 05/19/2026 04:00 PM Eastern
Extended Trading
$35.88 -0.01 (-0.01%)
As of 05/19/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,017.68 +29.59 (+2.99%)
Closing price 05/19/2026 03:59 PM Eastern
Extended Trading
$1,018.13 +0.45 (+0.04%)
As of 05/19/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$28.40 -0.29 (-1.01%)
Closing price 05/19/2026 04:00 PM Eastern
Extended Trading
$28.44 +0.04 (+0.12%)
As of 05/19/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.